Nasdaq Markets

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

By Lance Roberts:

The fiscal 2020 fourth-quarter earnings report that Take-Two Interactive (NASDAQ: TTWO) released on May 20 showed strong momentum building during the early weeks of the COVID-19 shelter-in-place period. The video game company's stock is up 4% year to date and 20% over the past 1

Americans are living longer and healthier lives. If you're a 62-year-old male, there's a 50% chance you'll live to see the year 2040. For women, add three years to that number, and for couples, there a one-in-four chance of one person living to be 95. These, of course, are aver

Deciding when to claim Social Security benefits is one of the most important choices you'll make. If you're considering starting your checks now because you're ready to retire or because the coronavirus has interfered with your ability to keep working, you need to make sure you'

The investment cases for buying in industrial supply company MSC Industrial (NYSE: MSM), multi-industry industrial giant 3M (NYSE: MMM), and package delivery company FedEx (NYSE: FDX) are going to be tested in the coming month. Here's what to look out for before buying these t

This article originally appeared on InHerSight.com, a website where women rate the female friendliness of their employers and get matched to companies that fit their needs.

Amid the coronavirus-fueled market downturn -- and the economic troubles that have followed -- many companies have slashed or outright suspended their dividend payments, much to the dismay of income-seeking investors. However, some companies look poised to ride out the current m

(RTTNews) - The week that just passed by saw the White House selecting vaccine candidates to Operation Warp Speed; new entrants in the COVID-19 drug development space; AstraZeneca's multi deals to produce and supply its vaccine and INOVIO's trials and tribulations, among others.

In 2018, 5.6 million people were newly awarded benefits from Social Security. These payments are one of the most important sources of income for retirees. 

All eyes were on Ontario, Canada-based cannabis company Canopy Growth's (NYSE: CGC) fourth-quarter fiscal 2020 results -- especially after Aurora Cannabis (NYSE: ACB) raised the stakes with impressive revenue growth in its third quarter. But Canopy's results weren't up to pa

Let's face it: There are a lot fewer bargains in the stock market than there were a couple of months ago. That's a natural consequence of the major stock market rebound.

Yesterday, there was some encouraging news on the jobs front. Despite predictions that May's unemployment rate would reach a record 20%, the jobless rate actually dropped from 14.7% in April to 13.3%. Of course, double-digit unemployment is still pretty dire, even if it represen

We're several months into the COVID-19 pandemic that has sent a chill down the spine of the global economy. There have been some big winners in the new normal, but now might be a good time to start sizing up potential market beaters in the scenario in which we start recovering f

When you think "medical robots," what name jumps to mind first?

Investors in Reed's, Inc. REED need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 18, 2020 $2.50 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility s

The Trump administration picked out five companies it believes are most likely to produce 2020’s holy grail – a vaccine for the coronavirus. Unfortunately, Novavax (NVAX) was not on the list.

Although the White House didn’t disclose what lay behind the choices, 5-star B.Riley FBR analyst Mayank Mamtani provided some possible explanations.

3 of the choices already have clinical studies in various degrees of progress (Moderna, AstraZeneca/Oxford University and Pfizer/BioNTech), whilst Novavax only began enrollment late last month. This implies to Mamtani that “speed to market entry” could be a major factor in the decision-making process.

Whilst “risk diversification and cost sharing,” and a preference for large companies (Johnson & Johnson, Merck) with the necessary balance sheet required to conduct the extensive and pricey vaccine development and manufacturing may also be contributing factors.

Even so, while those reasonings might explain the smaller player’s omission, Mamtani maintains Novavax should be added to the list.

Mamtani said, “We remain encouraged by the de-risked nature of NVAX's vaccine candidate, on the basis of the most extensive preclinical data generated to date, and now reviewed closely by the global scientific community residing with CEPI, WHO, and SII, as well as U.S. agencies such as CDC, NIH-NIAID, and BARDA. We believe adding NVAX's NVX-CoV2373 on the basis of its proprietary adjuvanted recombinant nanoparticle platform could further help diversify development risk as well as tap into a relatively clearer path to market and manufacturing scale-up that NVAX has made tangible progress on recently…”

To this end, Mamtani reiterated a Buy on NVAX and has a $74 price target, indicating the potential for 60% upside over the next year. (To watch Mamtani’s track record, click here)

All other 4 analysts to post a Novavax review over the last 3 months recommend the stock a Buy, too. A Strong Buy consensus rating is accompanied by a $49.20 price target, implying room for an 11% uptick in the months ahead. (See Novavax stock analysis on TipRanks)

To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Nexstar Media Group Inc (Symbol: NXST), where a total of 2,685 contracts have traded so far, representing approximately 268,500 underlying shares. That amounts to abou

In trading on Friday, shares of Levi Strauss & Co. (Symbol: LEVI) crossed above their 200 day moving average of $16.65, changing hands as high as $16.97 per share. Levi Strauss & Co. shares are currently trading up about 4.9% on the day. The chart below shows the one